Drug Development
Temsirolimus disrupts the angiogenic potential of tumor cells
Published in Women's Health Weekly, August 3rd, 2006
According to a study from Italy, "Mammalian target of rapamycin (mTOR) is increasingly recognized as a master regulator of fundamental cellular functions, whose deregulation may underlie neoplastic transformation and progression. Hence, mTOR has recently emerged as a promising target for therapeutic anticancer interventions in several human tumors, including breast cancer."
"Here, we investigated the antiangiogenic potential of temsirolimus (also known as CCI-779), a novel mTOR inhibitor currently in clinical development for the treatment of breast cancer and other solid tumors....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Back Pain
Chronic low back pain may be related to increased estrogen levels in women - Breast Cancer
Older women may exhibit cognitive function loss in conjunction with adjuvant chemotherapy - Cardiology
Peak oxygen consumption may not be as predictive in women for timing of cardiac transplant - Sexual & Reproductive Health
Polycystic ovary morphology in women with type 1 diabetes may be related to insulin therapy - Type 2 Diabetes
Risk of type 2 diabetes is increased in women with high dietary iron intake - Adverse Drug Reaction
Lamotrigine use during pregnancy linked to increased risk of cleft palate/cleft lip - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
